Percutaneous complete repair of failed mitral valve prosthesis: simultaneous closure of mitral paravalvular leaks and transcatheter mitral valve implantation – single-centre experience

Chad, Kliger; Angulo, Rocío; Maranan, Leandro; Kumar, Robert; Jelnin, Vladimir; Kronzon, Itzhak; Fontana, Gregory P.; Plestis, Konstadinos A.; Patel, Nirav; Perk, Gila; Ruiz, Carlos E.

doi:10.4244/eijy14m05_01

Cited by 31 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to TA and TS access, a direct transatrial access using a sheath placed directly into the left atrium via a right anterior thoracotomy was also used in two patients . The “TA + TS” access was utilized for the Melody valve . Transcatheter valves were used in all patients and included the SAPIEN XT ( n = 120, Edwards Lifesciences, Irvine, CA), SAPIEN ( n = 47, Edwards Lifesciences), SAPIEN 3 ( n = 26, Edwards Lifesciences), Melody ( n = 18, Medtronic, Minneapolis, MN), Tiara ( n = 4, Neovasc Inc, Richmond, Canada), Lotus ( n = 3, Boston Scientific, Natick, MA), Tendyne ( n = 1, Abbott, Abbott Park, IL), and Direct Flow Medical transcatheter valve system (DFM) ( n = 9, Direct Flow Medical Inc, Santa Rosa, CA).…”

Section: Resultsmentioning

confidence: 99%

Transcatheter mitral valve implantation for degenerated mitral bioprostheses or failed surgical annuloplasty rings: A systematic review and meta-analysis

Chen

Cheng

et al. 2018

J Card Surg

View full text Add to dashboard Cite

BackgroundTranscatheter mitral valve‐in‐valve (TMVIV) and valve‐in‐ring (TMVIR) implantation for degenerated mitral bioprostheses and failed annuloplasty rings have recently emerged as treatment options for patients deemed unsuitable for repeat surgery.MethodsA systematic literature review was conducted to summarize the data regarding the baseline characteristics and clinical outcomes of patients undergoing TMVIV and TMVIR procedures.ResultsA total of 245 patients (172 patients who underwent TMVIV surgery and 73 patients who underwent TMVIR surgery) were included in the study; 93.5% of patients experienced successful TMVIV or TMVIR implantation. The mortality rates at discharge, 30 days, and 6 months were 5.7%, 8.1%, and 23.4%, respectively. The transapical (TA) access route was used in most procedures (55.2%). The TA and transseptal (TS) access routes resulted in similar outcomes. No significant differences were observed in the short‐term outcomes between the patients who developed mitral stenosis versus mitral regurgitation as the mode of failure.ConclusionsTMVIV and TMVIR implantation for degenerated mitral bioprostheses and failed annuloplasty rings are safe and effective. Both procedures, via TA or TS access, can result in excellent short‐term clinical outcomes in patients with mitral stenosis or regurgitation, but long‐term follow‐up data are currently lacking to determine the durability of these procedures.

show abstract

Section: Resultsmentioning

confidence: 99%

Transcatheter mitral valve implantation for degenerated mitral bioprostheses or failed surgical annuloplasty rings: A systematic review and meta-analysis

Chen

Cheng

et al. 2018

J Card Surg

View full text Add to dashboard Cite

show abstract

“…Majority of the cases have been performed using the SAPIEN/SAPIEN XT balloon expandable valve (Edwards Lifesciences, Irvine, CA) and few with the self-expanding Melody valve (Medtronic, Minneapolis, MN) [11,12]. Further expansion of this indication to treat failed mitral valve repairs with complete or incomplete rings, that is valve-in-ring (VIR), has also been successful [13].…”

Section: Introductionmentioning

confidence: 99%

Factors influencing left ventricular outflow tract obstruction following a mitral valve‐in‐valve or valve‐in‐ring procedure, part 1

Bapat

Pirone

Kapetanakis

et al. 2015

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…guidance has been utilized for directed transcatheter access, as well as for procedural interventions in the treatment of both valvular and paravalvular regurgitation(28)(29)(30)(31).TRANSCATHETER THERAPIES FOR AR NATIVE VALVES. Currently, there are no approved THVs for the treatment of native valve AR in the United States.…”

mentioning

confidence: 99%

Transcatheter Therapies for the Treatment of Valvular and Paravalvular Regurgitation in Acquired and Congenital Valvular Heart Disease

Ruiz

Kliger

Perk

et al. 2015

Journal of the American College of Cardiology

Self Cite

View full text Add to dashboard Cite

Transcatheter therapies in structural heart disease have evolved tremendously over the past 15 years. Since the introduction of the first balloon-expandable valves for stenotic lesions with implantation in the pulmonic position in 2000, treatment for valvular heart disease in the outflow position has become more refined, with newer-generation devices, alternative techniques, and novel access approaches. Recent efforts into the inflow position and regurgitant lesions, with transcatheter repair and replacement technologies, have expanded our potential to treat a broader, more heterogeneous patient population. The evolution of multimodality imaging has paralleled these developments. Three- and 4-dimensional visualization and concomitant use of novel technologies, such as fusion imaging, have supported technical growth, from pre-procedural planning and intraprocedural guidance, to assessment of acute results and follow-up. A multimodality approach has allowed operators to overcome many limitations of each modality and facilitated integration of a multidisciplinary team for treatment of this complex patient population.

show abstract

Percutaneous complete repair of failed mitral valve prosthesis: simultaneous closure of mitral paravalvular leaks and transcatheter mitral valve implantation – single-centre experience

Abstract: Complete transcatheter repair of a degenerated mitral bioprosthesis with PVR can be performed in the high-risk patient. Accurate measurement is necessary prior to intervention, with concern for embolisation among the larger valve sizes (>31 mm).

Cited by 31 publications

References 26 publications

Transcatheter mitral valve implantation for degenerated mitral bioprostheses or failed surgical annuloplasty rings: A systematic review and meta-analysis

Transcatheter mitral valve implantation for degenerated mitral bioprostheses or failed surgical annuloplasty rings: A systematic review and meta-analysis

Factors influencing left ventricular outflow tract obstruction following a mitral valve‐in‐valve or valve‐in‐ring procedure, part 1

Transcatheter Therapies for the Treatment of Valvular and Paravalvular Regurgitation in Acquired and Congenital Valvular Heart Disease

Contact Info

Product

Resources

About